Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

Novel CRISPR Approach May Uncover Regulators of Lung Cancer Development
Newly Identified HER2 Mutations in Non–Small Cell Lung Cancer Focus on Exons 18 and 19
IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer
Can MCT4 Blockade Counter Resistance to Immunotherapy in LKB1-Mutant Lung Cancer?
Polymorphisms in Immune Checkpoint Proteins and Response to Immunotherapy
Preclinical Rationale for Combining KRAS and MCL1 Inhibitors in KRAS-Mutant Lung Cancer
AACR 2022: Overall Survival Update With Sotorasib in KRAS-Mutated Lung Cancer
AACR 2022: Nivolumab Plus Chemotherapy for Resectable Lung Cancer in Phase III CheckMate 816 Trial
AACR 2022: Neoadjuvant Durvalumab Alone or in Combination for Early-Stage Lung Cancer
Fam-Trastuzumab Deruxtecan-nxki Granted Priority Review in HER2-Mutant NSCLC
Update From LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
AACR 2022: Circulating Tumor DNA–Based Monitoring After Surgery for NSCLC
AACR 2022: Could Estrogen Derivatives Be Linked to Lung Cancer in Never-Smokers?
AACR 2022: Can Somatic Mutations and Ancestry Provide Risk Clues in Latin American Patients?
Targeting HER2 Mutations in NSCLC With Triplet Therapy
Does Adding Radiotherapy to Immunotherapy Improve Outcomes in Metastatic NSCLC?
5-Year PACIFIC Follow-Up: Durvalumab in Stage III NSCLC
ELCC 2022: How Prevalent Is Biomarker Testing in Patients With Advanced Lung Cancer?
Analyzing the Racial Disparities in Lung Cancer Screening Eligibility: Focus on 2021 USPSTF Criteria
FDA Brief: Companion Diagnostic Approved for NSCLC With EGFR Mutations
CHOICE-01 Trial: Toripalimab Plus Chemotherapy in Advanced NSCLC
Third-Generation EGFR TKI Abivertinib: Focus of Early-Stage Research in Lung Cancer
Can Routine Imaging for Lung Cancer Radiotherapy Planning Predict Cardiac Mortality?
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy Approved for Early-Stage NSCLC
Consolidation Therapy With Sugemalimab in Stage III Non–Small-Cell Lung Cancer
FDA Brief: Priority Review for Nivolumab Plus Chemotherapy as Neoadjuvant Treatment in Lung Cancer
Mobocertinib for EGFR Exon 20 Insertion–Positive Metastatic NSCLC
Role of Bupivacaine in Pain Management After Lobectomy for Early-Stage Lung Cancer
FDA Brief: New Drug Application Accepted for Adagrasib in KRAS G12C–Mutated NSCLC
Lung ART Trial: Postoperative Radiotherapy Under Study in Stage IIIAN2 NSCLC
CMS to Expand Eligibility Criteria for Low-Dose CT Screening for Lung Cancer
STS 2022: Surgical Wedge Resection Versus Stereotactic Radiation Therapy for in Situ NSCLC
STS 2022: Radiomic Approach to Predicting Histologic Subtype of Early-Stage Lung Adenocarcinoma
STS 2022: Does High-Intensity Surveillance After Surgery Improve Outcomes in Stage I NSCLC?
STS 2022: Surgical Approaches to Lobectomy for NSCLC: Lymph Node Upstaging and Overall Survival
Use of Patritumab Deruxtecan in EGFR Inhibitor–Resistant NSCLC
Use of Blood-Based Proteomic Test to Predict Outcomes With Immunotherapy for NSCLC
FDA Brief: Cemiplimab-rwlc Accepted for Review in First-Line Combination Therapy for Advanced Lung Cancer
Potential Correlation Between Stage Shift and Survival Among Patients With NSCLC
ZENITH20 Trial: Poziotinib in NSCLC After Prior Therapies
Global Study of Sequential Afatinib and Osimertinib in EGFR Mutation–Positive NSCLC
FDA Brief: Novel EGFR Inhibitor Granted Breakthrough Therapy Designation in Lung Cancer
Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC
Biomarker-Directed Analysis of First-Line Pembrolizumab-Based Therapies in NSCLC
Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC
Chemoradiation Plus Pembrolizumab for Locally Advanced NSCLC
Survival Rates for Lung Cancer: Increasing but Still Lower in People of Color
SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC
Stereotactic Body Radiation Therapy and Primary Tumor Control in NSCLC
SITC 2021: Prevalence of KRAS mutations in Advanced Nonsquamous NSCLC
SITC 2021: Immunomodulatory Effects of Neoadjuvant Nivolumab and Chemotherapy in NSCLC
How Does Ensartinib Compare With Crizotinib in First-Line Treatment of ALK-Positive NSCLC?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.